Boosting anandamide in adolescent rats reversed schizophrenia-like cognitive and social deficits through CB1 and CB2 receptors

Blocking anandamide breakdown in adolescent rats prevented cognitive and social impairments caused by earlier NMDA receptor disruption, with social effects mediated by CB1 and cognitive effects by CB2 receptors.

Bauminger, Hagar et al.·Schizophrenia bulletin·2022·Moderate EvidenceAnimal StudyAnimal Study
RTHC-03697Animal StudyModerate Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

The anandamide hydrolysis inhibitor URB597, given in late adolescence, reversed both novel object recognition deficits (via CB2 receptors) and social interaction abnormalities (via CB1 receptors) induced by early-adolescence MK-801 administration, while also normalizing glutamate and GABA marker expression in the prefrontal cortex.

Key Numbers

CB1 receptor mediated the reversal of social deficits; CB2 receptor mediated the reversal of cognitive deficits. URB597 also reversed glutamate and GABA abnormalities in the prelimbic prefrontal cortex.

How They Did This

Male rats received the NMDA receptor blocker MK-801 in early adolescence to induce schizophrenia-like symptoms, then received the anandamide hydrolysis inhibitor URB597 in late adolescence. Behavioral testing (novel object recognition, social interaction) and mRNA expression analysis of glutamate and GABA markers were performed in adulthood.

Why This Research Matters

This study identifies specific endocannabinoid receptor pathways for distinct schizophrenia symptoms, suggesting that targeting CB1 vs. CB2 receptors could address different symptom domains.

The Bigger Picture

The finding that different cannabinoid receptors mediate rescue of different symptom types (social vs. cognitive) suggests the endocannabinoid system could be a target for treatment-resistant symptoms of schizophrenia, which current antipsychotics often fail to address.

What This Study Doesn't Tell Us

Animal model only. MK-801 model does not fully replicate human schizophrenia. Only male rats tested. The therapeutic window (late adolescence) may not translate directly to human clinical application.

Questions This Raises

  • ?Would similar effects be seen in female rats?
  • ?Could selective CB2 agonists improve cognition in people with schizophrenia?
  • ?Is there a critical window for endocannabinoid intervention?

Trust & Context

Key Stat:
CB1 reversed social deficits; CB2 reversed cognitive deficits
Evidence Grade:
Rigorous animal study with clear mechanistic findings, but translation to humans is uncertain.
Study Age:
Published in 2022.
Original Title:
Anandamide Hydrolysis Inhibition Reverses the Long-Term Behavioral and Gene Expression Alterations Induced by MK-801 in Male Rats: Differential CB1 and CB2 Receptor-Mediated Effects.
Published In:
Schizophrenia bulletin, 48(4), 795-803 (2022)
Database ID:
RTHC-03697

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

How did the researchers create schizophrenia-like symptoms in rats?

They gave rats the NMDA receptor blocker MK-801 in early adolescence, which produced lasting cognitive deficits and social interaction problems similar to negative symptoms and cognitive deficits seen in schizophrenia.

What is URB597 and how does it work?

URB597 blocks the enzyme that breaks down anandamide, one of the brain's natural endocannabinoids. This increases anandamide levels, which then acts on CB1 and CB2 receptors to normalize behavior and brain chemistry.

Read More on RethinkTHC

Cite This Study

RTHC-03697·https://rethinkthc.com/research/RTHC-03697

APA

Bauminger, Hagar; Zaidan, Hiba; Akirav, Irit; Gaisler-Salomon, Inna. (2022). Anandamide Hydrolysis Inhibition Reverses the Long-Term Behavioral and Gene Expression Alterations Induced by MK-801 in Male Rats: Differential CB1 and CB2 Receptor-Mediated Effects.. Schizophrenia bulletin, 48(4), 795-803. https://doi.org/10.1093/schbul/sbab153

MLA

Bauminger, Hagar, et al. "Anandamide Hydrolysis Inhibition Reverses the Long-Term Behavioral and Gene Expression Alterations Induced by MK-801 in Male Rats: Differential CB1 and CB2 Receptor-Mediated Effects.." Schizophrenia bulletin, 2022. https://doi.org/10.1093/schbul/sbab153

RethinkTHC

RethinkTHC Research Database. "Anandamide Hydrolysis Inhibition Reverses the Long-Term Beha..." RTHC-03697. Retrieved from https://rethinkthc.com/research/bauminger-2022-anandamide-hydrolysis-inhibition-reverses

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.